Long-Term Efficacy, Safety of Metreleptin for Generalized Lipodystrophy
Investigators examined the safety and efficacy of metreleptin in patients with congenital or acquired generalized lipodystrophy.
Treatments
Semaglutide Superior to Other GLP-1 Analogues as Add-On to Basal Insulin in T2D
Overall, once-weekly semaglutide 1.0 mg as an add-on to basal insulin is the most efficacious GLP-1 receptor agonist in terms of reductions in HbA1c and body weight from baseline after 6 months of treatment.
Better Control With DPP-4 Inhibitors vs NPH Insulin in Type 2 Diabetes
Patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation rates and less hypoglycemia compared with patients starting NPH insulin.
SGLT2 Inhibitors Canagliflozin, Dapagliflozin Compared in Real-World Study
Study compared the real-world effectiveness of canagliflozin 300 mg vs dapagliflozin 10 mg on HbA1c reduction in patients with type 2 diabetes.
Risk for Fetal Loss Early in Pregnancy Not Greater With Noninsulin vs Insulin Therapy
Compared to standard insulin treatment, noninsulin antidiabetic agents did not present an increased risk for fetal losses or major malformations when used in the first trimester of pregnancy.
Crysvita Approved for the Treatment of X-Linked Hypophosphatemia
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
More Adverse Events and Higher Costs for Patients With RA on High-Dose Glucocorticoids
Investigators assessed the association between the cumulative dose of oral glucocorticoid treatment and expense associated with adverse events in patients with rheumatoid arthritis.
DPP-4 Inhibitors Not Tied to Increased Risk for Acute Pancreatitis in Seniors
Study provides evidence that DPP-4 inhibitors are not associated with an increased risk of acute pancreatitis in older adults overall. The positive association observed in patients with CVD could be due to chance or bias but merits further investigation.
Consensus Report Defines Treatment Success in β-Cell Replacement Therapy
IPITA and EPITA held a workshop to develop consensus for a joint statement on the definition of function and failure of current and future forms of β-cell replacement therapy.
Safety, Efficacy of Degludec/Liraglutide Fixed-Ratio Combination in Uncontrolled T2D
IDegLira provides an efficacious intensification option with noninferior glycemic control vs basal-bolus in patients with type 2 diabetes receiving 20 to 50 units of basal insulin with no renal impairment and HbA1c levels of 7% to 10%.
Next post in Type 2 Diabetes
